| scholarly article | Q13442814 |
| P356 | DOI | 10.3350/CMH.2014.20.3.274 |
| P8608 | Fatcat ID | release_mqrfzcrrjjdsnh7bddyq5ci7g4 |
| P932 | PMC publication ID | 4197176 |
| P698 | PubMed publication ID | 25320731 |
| P5875 | ResearchGate publication ID | 266974530 |
| P2093 | author name string | Jeong Han Kim | |
| So Young Kwon | |||
| Won Hyeok Choe | |||
| Soon Young Ko | |||
| Hee Won Moon | |||
| P2860 | cites work | Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. | Q53427565 |
| Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg. | Q53456897 | ||
| Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients | Q57782730 | ||
| Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir | Q58376651 | ||
| Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy | Q72087999 | ||
| Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B | Q80188303 | ||
| Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B | Q83258052 | ||
| Editorial: Measurement of HBsAg concentration during antiviral therapy of hepatitis B: who, when, and why | Q85054856 | ||
| Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. | Q30741676 | ||
| Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 | ||
| Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. | Q33610009 | ||
| Evaluation of the patient with hepatitis B | Q33896660 | ||
| Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | Q34302587 | ||
| The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus | Q34942505 | ||
| KASL Clinical Practice Guidelines: Management of chronic hepatitis B. | Q36153966 | ||
| Type and cause of liver disease in Korea: single-center experience, 2005-2010. | Q36306710 | ||
| Cellular and virological mechanisms of HBV drug resistance | Q36346620 | ||
| Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients | Q36365030 | ||
| Hepatitis B virus resistance to nucleos(t)ide analogues. | Q37593697 | ||
| Current status of liver diseases in Korea: hepatitis B. | Q37663499 | ||
| Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? | Q37969684 | ||
| Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia | Q39894574 | ||
| Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance | Q40178090 | ||
| Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. | Q42780978 | ||
| Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. | Q42876001 | ||
| Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy | Q42957928 | ||
| Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. | Q43136374 | ||
| Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study | Q43271385 | ||
| Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy | Q43910476 | ||
| Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment | Q44861367 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers | Q45375655 | ||
| Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. | Q45378210 | ||
| Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. | Q45385574 | ||
| Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. | Q45395245 | ||
| Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. | Q45398888 | ||
| Hepatitis B virus mutations associated with antiviral therapy | Q45417511 | ||
| Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. | Q45889605 | ||
| Virologic response and resistance to adefovir in patients with chronic hepatitis B. | Q46842950 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 274-282 | |
| P577 | publication date | 2014-09-25 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. | |
| P478 | volume | 20 |
| Q37097615 | The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy | cites work | P2860 |
Search more.